291 related articles for article (PubMed ID: 27102148)
1. The challenge of developmental therapeutics for adrenocortical carcinoma.
Costa R; Carneiro BA; Tavora F; Pai SG; Kaplan JB; Chae YK; Chandra S; Kopp PA; Giles FJ
Oncotarget; 2016 Jul; 7(29):46734-46749. PubMed ID: 27102148
[TBL] [Abstract][Full Text] [Related]
2. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
Barlaskar FM; Spalding AC; Heaton JH; Kuick R; Kim AC; Thomas DG; Giordano TJ; Ben-Josef E; Hammer GD
J Clin Endocrinol Metab; 2009 Jan; 94(1):204-12. PubMed ID: 18854392
[TBL] [Abstract][Full Text] [Related]
3. Update on adrenocortical carcinoma management and future directions.
Varghese J; Habra MA
Curr Opin Endocrinol Diabetes Obes; 2017 Jun; 24(3):208-214. PubMed ID: 28277340
[TBL] [Abstract][Full Text] [Related]
4. Molecular markers and targeted therapies for adrenocortical carcinoma.
Xu Y; Qi Y; Zhu Y; Ning G; Huang Y
Clin Endocrinol (Oxf); 2014 Feb; 80(2):159-68. PubMed ID: 24304415
[TBL] [Abstract][Full Text] [Related]
5. Adrenocortical Carcinoma: A Clinician's Perspective.
Elfiky A
Surg Pathol Clin; 2015 Dec; 8(4):751-4. PubMed ID: 26612225
[TBL] [Abstract][Full Text] [Related]
6. New targeted therapies for adrenocortical carcinomas.
Manso J; Pezzani R
Minerva Endocrinol; 2019 Mar; 44(1):70-81. PubMed ID: 29808641
[TBL] [Abstract][Full Text] [Related]
7. New insights and future perspectives in the therapeutic strategy of adrenocortical carcinoma (Review).
Stigliano A; Cerquetti L; Lardo P; Petrangeli E; Toscano V
Oncol Rep; 2017 Mar; 37(3):1301-1311. PubMed ID: 28184938
[TBL] [Abstract][Full Text] [Related]
8. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
[TBL] [Abstract][Full Text] [Related]
9. Management of Adrenocortical Carcinoma.
Jasim S; Habra MA
Curr Oncol Rep; 2019 Feb; 21(3):20. PubMed ID: 30798468
[TBL] [Abstract][Full Text] [Related]
10. Current Status and Future Direction in the Treatment of Advanced Adrenocortical Carcinoma.
Pak C; Yoon S; Lee JL; Yun T; Park I
Curr Oncol Rep; 2024 Apr; 26(4):307-317. PubMed ID: 38381366
[TBL] [Abstract][Full Text] [Related]
11. Emerging drugs for the treatment of adrenocortical carcinoma.
Sukrithan V; Husain M; Kirschner L; Shah MH; Konda B
Expert Opin Emerg Drugs; 2021 Jun; 26(2):165-178. PubMed ID: 33896321
[No Abstract] [Full Text] [Related]
12. The next generation of therapies for adrenocortical cancers.
Kirschner LS
Trends Endocrinol Metab; 2012 Jul; 23(7):343-50. PubMed ID: 22626690
[TBL] [Abstract][Full Text] [Related]
13. Estrogen related receptor α (ERRα) a promising target for the therapy of adrenocortical carcinoma (ACC).
Casaburi I; Avena P; De Luca A; Chimento A; Sirianni R; Malivindi R; Rago V; Fiorillo M; Domanico F; Campana C; Cappello AR; Sotgia F; Lisanti MP; Pezzi V
Oncotarget; 2015 Sep; 6(28):25135-48. PubMed ID: 26312764
[TBL] [Abstract][Full Text] [Related]
14. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells.
De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ
Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007
[TBL] [Abstract][Full Text] [Related]
15. Current and future medical therapy, and the molecular features of adrenocortical cancer.
Hubalewska-Dydejczyk A; Jabrocka-Hybel A; Pach D; Gilis-Januszewska A; Sokołowski G
Recent Pat Anticancer Drug Discov; 2012 Jan; 7(1):132-45. PubMed ID: 21854357
[TBL] [Abstract][Full Text] [Related]
16. Rottlerin as a novel chemotherapy agent for adrenocortical carcinoma.
Zhu Y; Wang M; Zhao X; Zhang L; Wu Y; Wang B; Hu W
Oncotarget; 2017 Apr; 8(14):22825-22834. PubMed ID: 28423559
[TBL] [Abstract][Full Text] [Related]
17. Wnt/β-catenin signaling pathway in the tumor progression of adrenocortical carcinoma.
Tai Y; Shang J
Front Endocrinol (Lausanne); 2023; 14():1260701. PubMed ID: 38269250
[TBL] [Abstract][Full Text] [Related]
18. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
19. IGF1-R inhibition and liposomal doxorubicin: Progress in preclinical evaluation for the treatment of adrenocortical carcinoma.
Beuschlein F; Jakoby J; Mentz S; Zambetti G; Jung S; Reincke M; Süss R; Hantel C
Mol Cell Endocrinol; 2016 Jun; 428():82-8. PubMed ID: 26994514
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
Costa R; Wesolowski R; Raghavan D
BJU Int; 2011 Nov; 108(10):1546-54. PubMed ID: 21883840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
